Form 4: Omeros Director Arnold Hanish Granted 15,000 Stock Options as Part of Annual Compensation

Omeros Corporation's Director, Arnold C. Hanish, received an annual grant of 15,000 stock options with an exercise price of $3.20 per share, vesting in 2026.

Summary

• Arnold C. Hanish, a Director of Omeros Corporation (OMER), was granted 15,000 stock options.
• The options have an exercise price of $3.20 per share.
• The grant date for these options was June 27, 2025, coinciding with the company's annual meeting of shareholders.
• The options will fully vest and become exercisable on the day before the 2026 annual meeting of Omeros Corporation shareholders.
• Vesting is contingent upon Mr. Hanish continuing to serve as a director through the vesting date.
• The expiration date for these options is June 27, 2035.
• This grant is part of Omeros Corporation's non-employee director compensation policy, which automatically grants options to eligible directors annually.

Sentiment

Score: 7

Explanation: The filing reports a routine, expected compensation event for a director, indicating stable corporate governance and alignment of interests. It does not contain information that would significantly alter the company's financial outlook or operations, hence a neutral to slightly positive sentiment reflecting standard practice.

Positives

• The stock option grant aligns with Omeros Corporation's established non-employee director compensation policy, indicating consistent corporate governance practices.
• The grant incentivizes continued service and alignment of director interests with shareholder value through equity ownership.

Negatives

• No specific negatives are indicated by this routine compensation filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The filing indicates a future vesting event for the granted stock options, contingent on the director's continued service through the day before the 2026 annual meeting of shareholders.

Management Comments

• "Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock."
• "This option will fully vest and become exercisable on the day before the date of the 2026 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date."

Industry Context

This Form 4 filing represents a routine insider transaction related to director compensation, common across publicly traded companies in all industries, including the biotechnology and pharmaceutical sector where Omeros Corporation operates. It reflects standard corporate governance practices for incentivizing non-employee directors.

Comparison to Industry Standards

• The practice of granting stock options as part of non-employee director compensation is a common industry standard across various sectors, including biotechnology and pharmaceuticals.
• The specific number of options (15,000) and exercise price ($3.20) would need to be compared against Omeros's peer group (e.g., other clinical-stage or commercial-stage biotech companies of similar market capitalization and revenue) to assess if it's within typical ranges for director compensation in the sector. Without specific peer data, a direct comparison is not possible, but the mechanism itself is standard.

Corporate Governance

Related Party Transactions

• The grant of 15,000 stock options to Director Arnold C. Hanish is a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholder value, as the options' value is tied to the company's stock performance. It represents a non-cash compensation expense.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The options are expected to vest on the day before the 2026 annual meeting of Omeros Corporation shareholders, provided the director continues to serve.

Key Dates

Recommendation

Keywords

Omeros Corporation, OMER, Stock Option Grant, Director Compensation, Insider Transaction, Form 4, Equity Award, Corporate Governance